

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

**(1) CHANGE OF JOINT COMPANY SECRETARY
AND AUTHORIZED REPRESENTATIVE; AND
(2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28
AND 8.17 OF THE LISTING RULES**

**RESIGNATION OF JOINT COMPANY SECRETARY AND AUTHORIZED
REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Alphamab Oncology (the “**Company**,” together with its subsidiaries, the “**Group**”) hereby announces that Ms. CHENG Qiulan (程湫滸) (“**Ms. Cheng**”) has tendered her resignation as a joint company secretary (the “**Joint Company Secretary**”) and has ceased to act as an authorized representative of the Company (the “**Authorized Representative**”) under Rule 3.05 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from April 8, 2026 due to her other work commitments.

Ms. Cheng has confirmed that she has no disagreement with the Board and there are no matters that need to be brought to the attention of the Stock Exchange and the shareholders of the Company in connection with her resignation as Joint Company Secretary and Authorized Representative.

**APPOINTMENT OF JOINT COMPANY SECRETARY AND AUTHORIZED
REPRESENTATIVE**

The Board further announces that Ms. JIANG Rui (蔣銳) (“**Ms. Jiang**”), has been appointed as the Joint Company Secretary, subject to the Waiver (defined below) to be granted by the Stock Exchange, and the Authorized Representative with effect from April 8, 2026.

Set out below are the biographical details of Ms. Jiang:

Ms. Jiang has 20 years of professional experience in internal control and audit, financial management, and listed company compliance management, with nearly ten years dedicated to the biopharmaceutical industry. Ms. Jiang joined the Group in May 2021 and currently serves as the senior director of internal control and audit, with additional oversight of the public relations function. Prior to joining the Group, Ms. Jiang served as a senior finance manager at Innovent Biologics (Suzhou) Co., Ltd. (信達生物製藥(蘇州)有限公司) (a subsidiary of Innovent Biologics, Inc., a company listed on the Stock Exchange (stock code: 1801)), and previously held positions including audit manager and senior internal audit manager at renowned institutions and enterprises such as PricewaterhouseCoopers and Canadian Solar Inc. (a company listed on the NASDAQ (ticker symbol: CSIQ)).

Ms. Jiang obtained a bachelor's degree in economics and a master's degree in national economics both from Nanjing University (南京大學) in the PRC. She holds professional qualifications including Chinese Certified Public Accountant (CICPA), Certified Tax Agent (CTA), and Certified Internal Auditor (CIA).

After the aforesaid changes, Ms. CHAN Lok Yee (“**Ms. Chan**”) will continue to serve as the other Joint Company Secretary. Ms. Chan is currently a senior manager of Corporate Services of Vistra Corporate Services (HK) Limited. She has over ten years of experience in providing a full range of company secretarial and compliance services to private and listed companies. Ms. Chan obtained a bachelor's degree in arts from The Hong Kong Polytechnic University and a master's degree of science in professional accounting and corporate governance from The City University of Hong Kong. She has been an associate member of The Hong Kong Institute of Chartered Secretaries (now known as The Hong Kong Chartered Governance Institute) and an associate member of The Institute of Chartered Secretaries and Administrators (now known as The Chartered Governance Institute) in the United Kingdom since 2015.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Listing Rules, a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of company secretary of the listed issuer by virtue of his/her academic or professional qualifications or relevant experience.

Although Ms. Jiang does not possess the relevant academic or professional qualifications or relevant experience as required under the Listing Rules, Ms. Jiang, as the senior director of internal control and audit of the Company, is familiar with the Group's business operations and strategies, corporate governance, financing and investment, and management of the Group and maintains a close working relationship with the Board. Accordingly, the Board considers Ms. Jiang is a suitable candidate to act as a Joint Company Secretary and believes that her appointment is in the interest of the Company and will facilitate the Group's corporate governance and on-going compliance with the Listing Rules.

In light of the above, the Company has made application to the Stock Exchange for a waiver from the strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules (the “**Waiver**”) for a period of three years (the “**Waiver Period**”), commencing from April 8, 2026, being the date of appointment of Ms. Jiang, as a Joint Company Secretary, on the conditions that (i) Ms. Jiang must be assisted by Ms. Chan throughout the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes. The appointment of Ms. Jiang as a Joint Company Secretary is subject to the Waiver to be granted by the Stock Exchange and the Company will make further announcement(s) in due course.

Before the end of the Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Ms. Jiang, having had the benefit of Ms. Chan’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Board would like to take this opportunity to express its appreciation for the valuable contributions of Ms. Cheng towards the Company during her tenure of service and warmly welcome Ms. Jiang for her new positions as the Joint Company Secretary and the Authorized Representative.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, April 8, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.